Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Drug: endometrial cancer - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Drug: Dostarlimab-gxly for dMMR endometrial cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Drug: Dostarlimab-gxly for dMMR endometrial cancer

New Drug: Dostarlimab-gxly for dMMR endometrial cancer
Study:
  • Multicenter, multicohort, open-abel trial (GARNET)
  • dMMR recurrent or advanced endometrial cancer who had progressed on or after a platinum-containing regimen
  • Dostarlimab-gxly q21 (n=141)
Efficacy:
  • ORR: 45.4% [37.0-54.0]; CR: 15.6%; PR:29.8%
  • 12 mos DOR: 85.9%
  • 24 mos DOR: 54.7%
Safety:
  • Any grade AEs: Asthenia (40%), diarrhea (25%), anemia (25%), neutropenia (12%), skin rash (14%).

BMJ 2022, 10 (1)

Oaknin A et al. ¨Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer l ¨

http://doi.org/10.1136/jitc-2021-003777

Reviewed by Elvin CHALABİYEV, MD on FEB 24, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More